



For Immediate Release

Corindus Vascular Robotics Announces Proposed Public Offering of Common Stock

Waltham, MA – May 26, 2015 – Corindus Vascular Robotics, Inc. (OTCQB: CVRS), a leading developer of precision vascular robotics, today announced that it plans to offer 11,000,000 shares of its common stock in an underwritten public offering. Corindus Vascular Robotics also expects to grant the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Corindus Vascular Robotics. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Cowen and Company and Stifel are acting as joint book-running managers for the offering. National Securities Corporation is acting as co-manager for the offering.

Corindus Vascular Robotics has filed a registration statement on Form S-1, including a preliminary prospectus, with the Securities and Exchange Commission, or SEC, relating to the public offering of the shares of common stock described above. A copy of the preliminary prospectus relating to these securities may be obtained, when available, by contacting Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806 or by faxing (631) 254-7140, or Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by calling (415) 364-2720 or by emailing syndprospectus@stifel.com. An electronic copy of the preliminary prospectus relating to the offering is also available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help physicians potentially provide better clinical outcomes and avoid some of the costs associated with complications through improper stent placement during manual PCI procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward-Looking Statements

Statements made in this press release by Corindus Vascular Robotics, Inc. that are not statements of historical or current facts may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations regarding future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of the CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, the completion, timing and size of the proposed offering, market conditions and risks associated with Corindus’ business and finances in general and other risks included in the “Risk Factors” section of Corindus’ Form S-1 registration statement and prospectus related to this offering and other Corindus filings with the SEC. There can be no assurance that Corindus Vascular Robotics will be able to complete the offering on the anticipated terms, or at all. Forward-looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Contact:

Corindus Vascular Robotics, Inc.

David W. Long

Chief Financial Officer

(508) 653-3335 ext. 228

david.long@corindus.com